A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 48/00 (2006.01) A61K 31/70 (2006.01) C07K 14/47 (2006.01)
Patent
CA 2250428
A plasmid-based vaccine is provided herein based on the combination of DNA segments coding for one or more B cell epitopes of CETP and one or more broad range helper T cell epitopes. Administration of the plasmids as a vaccine to a vertebrate subject provides an immune response to the subject's endogenous CETP and modulation of CETP activity, leading to prevention or reversal of various manifestations of heart disease. The vaccines provide an advantageous strategy for the prevention or treatment of atherosclerosis.
Vaccin plasmidique à base d'une association de segments d'ADN codant pour un ou plusieurs épitopes de lymphocytes B de la protéine de transfert d'ester de cholestéryle (CETP) et un ou plusieurs épitopes de lymphocytes T auxiliaires universels. L'administration des plasmides sous forme de vaccin à un sujet vertébré entraîne une réaction immunitaire au CETP endogène du sujet et la modulation de cette activité, ce qui permet de prévenir des affections cardiaques ou d'inverser le processus de diverses manifestations de ce type d'affections. Ces vaccins constituent une stratégie avantageuse de prévention ou de traitement de l'athérosclérose.
Avant Immunotherapeutics Inc.
Smart & Biggar
T. Cell Sciences Inc.
LandOfFree
Plasmid-based vaccine for treating atherosclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Plasmid-based vaccine for treating atherosclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Plasmid-based vaccine for treating atherosclerosis will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1346535